• iBio Inc., of Newark, Del., reported data from preclinical vaccine applications of its lichenase fusion-protein technology suggesting that lichenase-fused antigens prolonged vaccine effectiveness and lowered the required antigen dose in tests conducted with antigens from anthrax, plague and malaria.